Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Specialty Channel
News
Osimertinib Plus Selumetinib Shows Limited Activity Following First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
06/26/2026
Emily Estrada
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of...
06/26/2026
Oncology
News
Benmelstobart Plus Anlotinib as Potential New First-Line Option in Advanced NSCLC
05/29/2026
Emily Estrada
Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.
Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.
Benmelstobart plus chemotherapy...
05/29/2026
Oncology
News
Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
05/29/2026
Stephanie Holland
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
05/29/2026
Oncology
News
Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer
05/27/2026
Emily Estrada
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3...
05/27/2026
Oncology
News
Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC
05/27/2026
Emily Estrada
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase...
05/27/2026
Oncology
FDA Approval
FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC
02/26/2026
Emily Estrada
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the...
02/26/2026
Oncology
News
Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer
01/21/2026
Stephanie Holland
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/21/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Amivantamab and Hyaluronidase-lpuj
12/18/2025
Emily Estrada
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA...
12/18/2025
Oncology
News
Amivantamab Plus Lazertinib Demonstrates Robust Activity in Atypical EGFR-Mutated Advanced NSCLC
12/04/2025
Stephanie Holland
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the...
12/04/2025
Oncology
News
Sevabertinib Demonstrates Robust Antitumor Activity in HER2-Mutated Non-Small Cell Lung Cancer
12/04/2025
Stephanie Holland
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2...
12/04/2025
Oncology

News

News
Osimertinib Plus Selumetinib Shows Limited Activity Following First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
06/26/2026
Emily Estrada
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of...
06/26/2026
Oncology
News
Benmelstobart Plus Anlotinib as Potential New First-Line Option in Advanced NSCLC
05/29/2026
Emily Estrada
Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.
Benmelstobart plus chemotherapy followed by maintenance benmelstobart and anlotinib significantly improved progression-free survival compared with a tislelizumab-based regimen in first-line EGFR/ALK/ROS1-wild type advanced non-squamous NSCLC.
Benmelstobart plus chemotherapy...
05/29/2026
Oncology
News
Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
05/29/2026
Stephanie Holland
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
05/29/2026
Oncology
News
Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer
05/27/2026
Emily Estrada
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3...
05/27/2026
Oncology
News
Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC
05/27/2026
Emily Estrada
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase...
05/27/2026
Oncology
FDA Approval
FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC
02/26/2026
Emily Estrada
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the...
02/26/2026
Oncology
News
Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer
01/21/2026
Stephanie Holland
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/21/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Amivantamab and Hyaluronidase-lpuj
12/18/2025
Emily Estrada
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA...
12/18/2025
Oncology
News
Amivantamab Plus Lazertinib Demonstrates Robust Activity in Atypical EGFR-Mutated Advanced NSCLC
12/04/2025
Stephanie Holland
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the...
12/04/2025
Oncology

Interactive Features

Quiz
Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Repotrectinib for ROS1 Fusion-Positive NSCLC
02/05/2024
02/05/2024
Oncology
Quiz
Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
Treatment-Related Adverse Events With Nivolumab Plus Ipilimumab for NSCLC
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
Quiz: Survival Outcomes With Pembrolizumab for Nonsquamous NSCLC
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology

Recent News

News
Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
05/29/2026
Stephanie Holland
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
05/29/2026
Oncology
News
Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer
05/27/2026
Emily Estrada
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3...
05/27/2026
Oncology
News
Neoadjuvant Lorlatinib Produces Durable Early Outcomes in ALK-Positive NSCLC
05/27/2026
Emily Estrada
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase...
05/27/2026
Oncology
FDA Approval
FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC
02/26/2026
Emily Estrada
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the...
02/26/2026
Oncology
News
Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer
01/21/2026
Stephanie Holland
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 3 ARTS trial, adjuvant aumolertinib demonstrated strong clinical promise with a manageable safety profile among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/21/2026
Oncology
News
Andamertinib Demonstrates Clinical Promise for Pretreated Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/13/2026
Stephanie Holland
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion...
Results from the phase 2 KANNON...
01/13/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Formulation of Amivantamab and Hyaluronidase-lpuj
12/18/2025
Emily Estrada
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA approved a subcutaneous formulation of amivantamab and hyaluronidase-lpuj for adult patients across all indications previously approved for intravenous amivantamab.
On December 17, 2025, the FDA...
12/18/2025
Oncology
News
Amivantamab Plus Lazertinib Demonstrates Robust Activity in Atypical EGFR-Mutated Advanced NSCLC
12/04/2025
Stephanie Holland
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the CHRYSALIS-2 study demonstrate that amivantamab plus lazertinib shows clinically meaningful antitumor activity in patients with advanced non-small cell lung cancer who harbor atypical EGFR mutations.
Updated results from the...
12/04/2025
Oncology
News
Sevabertinib Demonstrates Robust Antitumor Activity in HER2-Mutated Non-Small Cell Lung Cancer
12/04/2025
Stephanie Holland
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2...
12/04/2025
Oncology
News
MET Exon 2 Skipping Mutation Associated With Self-Regulatory Mechanism for Advanced NSCLC
11/20/2025
Emily Estrada
A retrospective analysis presented at the 2025 Association for Molecular Pathology Annual Meeting & Expo found that MET exon 2 skipping mutations are associated with a self-regulatory mechanism among patients with non-small cell lung cancer.
A retrospective analysis presented at the 2025 Association for Molecular Pathology Annual Meeting & Expo found that MET exon 2 skipping mutations are associated with a self-regulatory mechanism among patients with non-small cell lung cancer.
A retrospective analysis...
11/20/2025
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use